Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1076
Abstract: Roxadustat inhibits breast cancer resistance protein and organic anion transporting polypeptide 1B1, which can affect coadministered statin concentrations. Three open‐label, 1‐sequence crossover phase 1 studies in healthy subjects were conducted to assess effects from steady‐state… read more here.
Keywords: roxadustat; label sequence; sequence crossover; atorvastatin ... See more keywords
Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.597
Abstract: Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor in late‐stage clinical development for the treatment of anemia in chronic kidney disease. Spherical carbon adsorbent (SCA) is used in patients with chronic kidney disease and has… read more here.
Keywords: pharmacokinetics roxadustat; time; drug; effect ... See more keywords
The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review
Sign Up to like & getrecommendations! Published in 2021 at "International Urology and Nephrology"
DOI: 10.1007/s11255-020-02693-7
Abstract: Background Anemia is a common complication for patients with kidney disease. Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), which is a newly approved oral drug for anemia. We performed this study… read more here.
Keywords: anemia; analysis; safety; disease ... See more keywords
Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration.
Sign Up to like & getrecommendations! Published in 2022 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2022.114939
Abstract: Kidney injury often causes anemia due to a lack of production of the erythroid growth factor erythropoietin (EPO) in the kidneys. Roxadustat is one of the first oral medicines inducing EPO production in patients with… read more here.
Keywords: hypoxia inducible; effective duration; esterification; inducible factors ... See more keywords
Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the Formosan Medical Association = Taiwan yi zhi"
DOI: 10.1016/j.jfma.2021.06.004
Abstract: BACKGROUND/PURPOSE Roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, promotes erythropoiesis and regulates iron metabolism. This study investigated the efficacy and safety of roxadustat in Chinese patients with anemia on peritoneal dialysis (PD). METHODS One… read more here.
Keywords: week; trial; anemia peritoneal; treatment ... See more keywords
Therapeutic Potential of the Prolyl Hydroxylase Inhibitor Roxadustat in a Mouse Hindlimb Lymphedema Model.
Sign Up to like & getrecommendations! Published in 2023 at "Lymphatic research and biology"
DOI: 10.1089/lrb.2022.0071
Abstract: Background: Lymphedema is an intractable disease with no curative treatment available. Conservative treatment is the mainstay, and new drug treatment options are strongly needed. The purpose of this study was to investigate the effect of… read more here.
Keywords: roxadustat; lymphedema; group; hindlimb lymphedema ... See more keywords
FC 071ENHANCED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE (HMGCR) MAY CONTRIBUTE TO THE LOWERING OF LDL CHOLESTEROL SEEN WITH ROXADUSTAT IN CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab118.001
Abstract: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in China and Japan for the treatment of anemia in patients with chronic kidney disease (CKD). In Phase 3 clinical studies, roxadustat was shown… read more here.
Keywords: roxadustat; cholesterol; hmgcr; effect ... See more keywords
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13609
Abstract: Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat may be beneficial for patients who inadequately respond to erythropoiesis‐stimulating agents… read more here.
Keywords: eri; treatment; roxadustat darbepoetin; darbepoetin alfa ... See more keywords
Roxadustat promotes angiogenesis through HIF‐1α/VEGF/VEGFR2 signaling and accelerates cutaneous wound healing in diabetic rats
Sign Up to like & getrecommendations! Published in 2019 at "Wound Repair and Regeneration"
DOI: 10.1111/wrr.12708
Abstract: Diabetic foot ulcers are a major health‐care burden worldwide. One primary cause of the delayed wound healing in diabetic patients is impaired function of the hypoxia‐inducible factor‐1α/vascular endothelial growth factor (HIF‐1α/VEGF) axis, which results in… read more here.
Keywords: hif vegf; wound healing; healing diabetic; roxadustat ... See more keywords
Effect of Roxadustat on Factors Associated with Renal Fibrosis and Efficacy
Sign Up to like & getrecommendations! Published in 2022 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2022/4764254
Abstract: Objective We investigated the effect of roxadustat on factors associated with renal fibrosis and efficacy. Methods. Sixty patients meeting the inclusion criteria between January 2021 and October 2021 were equally distributed into observation (roxadustat) group… read more here.
Keywords: roxadustat; effect roxadustat; factors associated; efficacy ... See more keywords
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis
Sign Up to like & getrecommendations! Published in 2020 at "Nephron"
DOI: 10.1159/000508100
Abstract: Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) chronic kidney disease (CKD). Objective: Multicenter, randomized, open-label, noncomparative, phase 3 study… read more here.
Keywords: treatment; study; treatment anemia; rate ... See more keywords